Harbor Disruptive Innovation ETF (INNO)
- Previous Close
15.22 - Open
15.15 - Bid 15.28 x 800
- Ask --
- Day's Range
15.19 - 15.30 - 52 Week Range
11.40 - 16.48 - Volume
2,039 - Avg. Volume
2,238 - Net Assets 30.77M
- NAV 15.20
- PE Ratio (TTM) 41.96
- Yield 0.00%
- YTD Daily Total Return 5.12%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.75%
Under normal market conditions, the fund invests primarily in equity securities, principally common stocks, of companies selected based on their potential for growth tied to disruptive innovation. The advisor defines “disruptive innovation” as the development of new products, services, technologies and/or other advancements that could disrupt and displace existing businesses and business models over time. While the fund invests primarily in securities of U.S. companies, it may invest up to 25% of its assets in foreign securities, including those located in emerging market countries.
Harbor
Fund Family
Large Growth
Fund Category
30.77M
Net Assets
2021-12-01
Inception Date
Performance Overview: INNO
Trailing returns as of 6/7/2024. Category is Large Growth.
People Also Watch
Holdings: INNO
Top 10 Holdings (28.49% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: INNO
Microsoft Earnings: Good Result Punctuated by Strong AI Demand Within Azure
Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).
RatingPrice TargetJohnson & Johnson Earnings: Growth Outlook Slowing After Solid 2023, but Pipeline Holds Upside
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetOracle Earnings: Reported and Guided Revenue Come in Light; Shares Still Overvalued As Stock Tumbles
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
RatingPrice TargetLululemon’s Popularity Provides an Advantage but Envious Competitors Remain
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 670 company-owned stores in 19 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
RatingPrice Target